Autoimmune Diseases
Feature
ACR CRISS: A way forward for scleroderma treatment trials?
From the Journals
Short-term lung function better predicts mortality risk in SSc
Surrogate measures of lung disease progression may help to determine the need for early intervention.
Conference Coverage
Development of reversible B-cell inhibitor XmAb5871 for SLE moves forward
Conference Coverage
Fear of blindness hobbles hydroxychloroquine treatment of SLE
Conference Coverage
Tofacitinib impresses in first trial for dermatomyositis
CHICAGO – Evidence of strong clinical efficacy noted.
Conference Coverage
Scleroderma SCOT trial findings hold similar in lung disease
CHICAGO –
Conference Coverage
Genetic profile flags scleroderma patients with best HSCT responses
CHICAGO – Gene-expression profiling identifies four scleroderma subgroups, including one subgroup with the best response to stem cell transplant...
Conference Coverage
Dueling SLE classification criteria: And the winner is...
CHICAGO – “We have an embarrassment of criteria for lupus right now, and everyone wants to know if one is better than the others,” Dr. Michelle A...
Conference Coverage
Leflunomide-hydroxychloroquine combo shows promise in primary Sjögren’s pilot study
CHICAGO – Randomized, placebo-controlled trial may support evidence for an added benefit of the two drugs together.
Conference Coverage
SLE low-disease definition receives prospective validation
CHICAGO – Researchers validated a proposed definition of low disease activity state in lupus patients in a large, prospective, multicenter study...
News
Ablation plus transplant for severe scleroderma shows 11-year benefits
CHICAGO – Follow-up to 11 years of patients with severe scleroderma in a stem cell treatment trial documented long-term durability and safety.